Unlocking the Power of Systems Thinking in Policymaking: A Path to Stronger Health Systems

By HEOR Staff Writer

July 3, 2023

Discover the untapped potential of systems thinking in shaping effective policies and practices published in a new article. 

Traditionally seen as too conceptual for policy relevance, systems thinking is now gaining traction in high-income countries, with governments embracing adaptive leadership and systemic evaluations. 

But what about low- and middle-income countries? Resource constraints often hinder the institutionalization of systems thinking, making it challenging to replicate successful examples.

To overcome this, the study proposes three key steps:

1️⃣ Theorise and clarify the terminology of applied systems thinking in health policy and systems research (HPSR). By utilising systems modeling and other tools, we can better understand the interactions between interventions and their contexts. 

2️⃣ Encourage greater government investment and institutional incentives to foster long-term collaboration and science-policy partnerships. This will enhance the capacities and practice of systems thinking in policymaking. 

3️⃣ Advocate for funding norms that enable systems thinking in LMICs. Pooling resources and fostering networked institutions can address complexity and adaptive approaches, leading to more impactful outcomes. 

 

To read the full article click on the link below. 

Reference url

Recent Posts

Retracted Trial Publication
Retracted Trial Publication Undermines Support for Avacopan in AAV Treatment

By João L. Carapinha

July 1, 2026

The Retracted Trial Publication of the ADVOCATE study has eliminated the central evidence that supported approval of Tavneos (avacopan) for severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (AAV). At the request of two lead academic authors, the
Teplizumab Type 1 Diabetes
Recommendation for Teplizumab Type 1 Diabetes Routine Use

By João L. Carapinha

June 23, 2026

Teplizumab for Type 1 Diabetes now has a clear route to routine NHS use after NICE recommended the therapy for delaying progression from stage 2 to stage 3 disease in people aged 8 and older. The decision, dependent on a confidential commercial discount, offers families more time before insulin d...
CAPVAXIVE Pediatric Vaccine Approval
Advancing CAPVAXIVE Pediatric Vaccine Approval for High-Risk Youth

By João L. Carapinha

June 19, 2026

The CAPVAXIVE Pediatric Vaccine Approval expands options for children and adolescents aged 2 through 17 who have completed their primary pediatric pneumococcal series yet face elevated risk due to chronic conditions such as diabetes, heart disease, kidney disease, liver disease, or lung disease. ...